Technical insights and market analysis on breakthrough discoveries in biology, chemistry, and engineering. Explore our latest research findings and industry perspectives.
The biopharmaceutical industry is at a watershed moment. The long-standing paradigm of antibody discovery—a costly, decade-long process of brute-force screening and serendipity—is giving way to an era of rational, de novo design driven by AI and high-resolution single-cell analysis.
AI is undeniably revolutionizing biopharma, but beneath the hype lies a growing crisis: AI is running out of high-quality, biologically relevant data. The challenge is no longer about getting more data, but about getting the right data.
Characterizing the HIV latent reservoir presents a formidable technical challenge. Vivid BioLabs has developed High-Resolution Integrated Viral Enrichment sequencing (HIV-seq) to provide comprehensive, scalable solutions for deep reservoir characterization.